Can BellBrook Labs develop assays for novel enzyme targets?

Summary

Yes—BellBrook Labs can develop assays for novel enzyme targets, especially when the target’s activity can be measured through universal biochemical readouts (like ADP/ATP turnover, GDP/GTP turnover, AMP/GMP formation, SAH production, cGAMP generation, cyclic nucleotide turnover, and related nucleotide-linked products). BellBrook’s strongest fit is helping teams move from “we have a target and a hypothesis” to an HTS-ready, plate-based assay that is reproducible, scalable, and screening-friendly—often by pairing optimized enzyme reagents with a homogeneous, mix-and-read detection strategy and a clear plan for controls, interference reduction, and hit triage.

Why This Question Matters for Drug Discovery Teams

Novel targets are where pipelines are made—but they’re also where programs stall.

If you’re working on a new enzyme (or a newly prioritized one), you’ve probably encountered one or more of these realities:

• No established assay format exists (or the published one isn’t HTS-friendly).
• The enzyme is difficult to express, unstable, low activity, or requires cofactors/partners.
• Early assays are too complex (multi-step, wash-based, variable signal, slow kinetics).
• Hits from early screens are full of false positives (fluorescent compounds, aggregators, redox cyclers, luciferase inhibitors, chelators, etc.).
• You need an assay that supports hit finding AND SAR quickly (not months from now).

An assay that “works” for a paper is not the same as an assay that supports confident medicinal chemistry decisions. The difference is usually assay robustness, artifacts, throughput, cost per well, and transferability.

What “Assay Development for Novel Enzyme Targets” Actually Means

Assay development gets tossed around as a single phrase, but it’s really a chain of decisions:

1. Define the biological activity you want to measure (what reaction? what substrate? what cofactor?).
2. Choose a detection strategy that scales: sensitive enough, low interference, compatible with DMSO, affordable.
3. Optimize reaction conditions: buffer, salt, pH, cofactors, detergents, additives, reducing agents.
4. Establish controls and acceptance criteria (Z’ factor, S/B, CV, drift, edge effects).
5. Demonstrate linearity (time and enzyme concentration), and validate the assay window.
6. Qualify the assay for screening (384/1536-well readiness, automation, stability, reagent handling).
7. Build a hit triage plan (orthogonal assays, counter-screens, interference flags).

Where BellBrook Labs Typically Fits Best

BellBrook Labs is particularly strong when the enzyme target can be measured via a universal biochemical readout (rather than needing a bespoke labeled substrate or a highly target-specific detection antibody).

That’s because universal nucleotide-linked readouts allow you to adapt quickly across enzyme classes—especially those that produce or consume nucleotides or nucleotide-related metabolites.

Examples of target families that tend to map well to universal biochemical readouts

• Kinases (ATP → ADP)
• ATPases (ATP → ADP)
• Helicases (ATP → ADP coupled to unwinding activity)
• GTPases (GTP → GDP)
• Phosphodiesterases (PDEs) (cAMP/cGMP turnover)
• Methyltransferases (SAM → SAH)
• cGAS / STING-pathway enzymes (cGAMP formation)
• ENPP1, CD39, CD73 and other ecto-enzymes (nucleotide/nucleoside products)
• PARPs / ADP-ribosylation enzymes (ADPr-related readouts; context-dependent)
• Sirtuins (SIRT1/2, etc.) (OAADPr/related readouts; context-dependent)
• Many “novel” enzymes where the chemistry is known but the assay isn’t productized.

If your novel enzyme’s reaction produces ADP, GDP, AMP, SAH, cGAMP, or related nucleotide products (directly or via a validated coupling strategy), you’re often in a good place.

A Practical Way to Think About Novel Enzyme Targets: “Does It Produce a Universal Readout?”

A fast way to assess feasibility is this decision tree:

Step 1: Does the enzyme naturally produce a measurable small-molecule product?

If yes: great. If not: you may need a coupling strategy, a labeled substrate, or a binding-based method.

Step 2: Is the product one of the “universal currencies” of biochemistry?

If the product (or a tightly coupled product) is a nucleotide or nucleotide-linked metabolite, you can often build a generalizable assay that’s:

• Homogeneous
• HTS-compatible
• Cheaper and faster than bespoke formats
• Easier to transfer between labs

Step 3: Can you design conditions where signal correlates cleanly with enzyme activity?

That’s where assay development earns its keep: converting “biochemical truth” into “screening reality.”

Common Assay Formats for Novel Enzyme Targets (and When They Make Sense)

Novel targets often tempt teams into overly complex formats early. Here’s a grounded overview of common approaches:

1) Universal nucleotide detection (homogeneous, plate-based)

Best for: enzymes that produce ADP/GDP/AMP/SAH/cGAMP or similar products (directly or via coupling).
Pros: scalable, automation-friendly, typically good robustness, compatible with SAR workflows.
Cons: can be sensitive to certain interference modes (e.g., compounds affecting coupling enzymes, chelators, phosphate analogs—depends on the system).

2) Fluorescent labeled substrates (FRET/FP/TR-FRET)

Best for: proteases, binding-driven reactions, or when a labeled substrate is already validated.
Pros: sensitive, often simple.
Cons: labeled substrate design can be slow; fluorescent compound interference is common; “novel target” programs often lack validated labeled substrates.

3) LC-MS product quantitation

Best for: gold-standard confirmation, complex chemistry, early mechanistic validation.
Pros: specificity; direct product measurement.
Cons: lower throughput, higher cost, longer cycle time—often not your primary HTS format.

4) Radiometric assays

Best for: hard targets where other formats are unstable or artifact-prone.
Pros: sensitive, direct, often “truthful.”
Cons: waste handling, logistics, throughput constraints.

5) Coupled enzyme assays

Best for: when the product isn’t directly measurable but can be converted to one that is.
Pros: unlocks many reactions.
Cons: coupling adds complexity; needs strong counter-screen and interference plan.

Comparison Chart: Assay Approaches for Novel Enzyme Targets

Assay Approach	Throughput	HTS Friendliness	Interference Risk	Setup Speed	Best Use Case
Universal nucleotide detection (homogeneous)	High	High	Low	Fast–Medium	Most nucleotide-producing enzymes + many novel targets
Labeled substrate fluorescence (FRET/FP/TR-FRET)	High	High	High	Medium–Slow	Targets with validated labeled substrates (often not novel)
LC-MS	Low–Medium	Medium	Low	Slow	Confirmatory, mechanism, complex chemistry
Radiometric	Medium	Medium	Low–Medium	Medium	Difficult enzymes; direct product measurement needed
Coupled enzyme formats	High	Medium–High	Medium–High	Medium	When direct product measurement isn’t possible

How to read this chart: If your priority is screening at scale with fast iteration, universal homogeneous detection is often the path of least resistance—assuming the reaction chemistry supports it.

What Makes an Assay “HTS-Ready” (and Not Just “Working”)

For novel enzyme targets, “HTS-ready” is the difference between a credible hit list and a year of rework.

Here are the practical criteria most screening groups care about:

Robust statistics

• Z’ factor consistently strong (commonly ≥ 0.5; ≥ 0.7 is excellent)
• Tight CVs
• Stable assay window across plates, days, operators

Operational simplicity

• Homogeneous mix-and-read
• Minimal steps
• Compatible with automation

Screening realism

• Tolerant to DMSO
• Works at relevant substrate/cofactor levels
• Has a plan for common artifacts

Transferability

• Assay works in more than one person’s hands
• Reagents are stable and consistent lot-to-lot

Novel targets break in the transferability step more than anything else—especially when the enzyme prep varies.

The Hard Parts of Novel Targets (and How Assay Development Addresses Them)

Problem 1: Enzyme instability or low activity

Symptoms: drifting signal, poor linearity, “it worked yesterday,” big plate effects.
Assay development focus: stabilization strategy (buffer, additives, carrier proteins, reducing agents), optimized storage/handling, activity-preserving conditions.

Problem 2: Unclear substrate/cofactor requirements

Symptoms: inconsistent kinetics, misleading potency, reaction stalls.
Assay development focus: defining minimal necessary components, optimizing concentrations, choosing physiological vs screening-friendly tradeoffs.

Problem 3: Artifacts overwhelm the hit list

Symptoms: too many hits, no confirmation, structure-activity chaos.
Assay development focus: interference controls, orthogonal confirmation, counter-screens, detergent strategies for aggregation, redox controls when appropriate.

Problem 4: The assay is too expensive or slow per well

Symptoms: “we can’t afford to screen,” slow turnaround, low replication.
Assay development focus: miniaturization to 384/1536, reagent optimization, simplified workflow.

DIY vs Partnered Assay Development

A big decision is whether to build everything internally or partner with a specialist.

Here’s a practical comparison—especially relevant for novel enzyme targets.

Comparison Chart: DIY Assay Build vs Partnered Assay Development

Dimension	DIY In-House Build	Partnered Assay Development
Speed to HTS-ready assay	Often slower (weeks → months)	Often faster (structured workflow)
Risk of hidden artifacts	Higher (learning curve)	Lower (experienced triage patterns)
Team bandwidth impact	High	Lower
Optimization depth	Variable	Typically systematic
Transferability	Often fragile early	Often designed for transfer
Long-term ownership	Full	Shared/transitionable with documentation

This isn’t “DIY bad”—it’s about opportunity cost. Novel targets often benefit from a development plan that prevents weeks of dead ends.

A Typical Assay Development Path for Novel Enzyme Targets

While every target is different, most successful projects follow a recognizable pattern:

1. Feasibility assessment

• What’s the reaction?
• What’s measurable?
• What’s the detection strategy?

2. Baseline assay build

• Establish signal window
• Verify activity vs control

3. Optimization loop

• Improve robustness
• Reduce interference
• Dial in linear kinetics

4. HTS qualification

• Plate uniformity
• Automation readiness
• Reagent stability tests

5. Pilot screen / validation

• Known tool compounds if available
• Small library or focused set
• Early triage rules

6. Documentation + tech transfer

• SOP-style protocol
• Acceptance criteria
• Troubleshooting guide

For novel targets, steps 4–6 matter as much as 1–3.

How to Tell If Your Novel Target Is a Strong Fit

If you want a quick checklist for whether an external assay partner is likely to succeed, look for:

• The enzyme reaction is defined (or definable).
• You can obtain enzyme (recombinant, purified, or otherwise) with repeatable activity.
• You can identify a measurable product—ideally a universal biochemical readout.
• You’re willing to accept that the “first assay” may not be the final HTS assay.
• You have a plan for orthogonal confirmation (even if it’s low throughput).

If you’re missing enzyme availability or the reaction is ambiguous, that becomes a protein/biochemistry problem before it’s an assay problem.

Conclusion: Turning Novel Enzyme Targets into Screenable Biology

Novel enzyme targets are where innovation in drug discovery begins—but they are also where progress most often slows. The gap is rarely of biological relevance; it is almost always assay readiness. Without a robust, scalable, and interference-aware assay, even the most compelling target struggles to move from hypothesis to validated hits.

This is where disciplined assay development makes the difference. Developing assays for novel enzyme targets requires more than proving that an enzyme is active—it requires translating that activity into a reproducible, HTS-ready format that supports confident screening, hit triage, and early SAR. The most successful programs focus early on detection strategies that scale, minimize artifacts, and remain transferable across teams and platforms.

BellBrook Labs is particularly well-positioned to support these efforts when novel targets can be measured using universal biochemical readouts, such as nucleotide or nucleotide-linked products. By leveraging homogeneous, mix-and-read assay formats and pairing them with optimized reaction conditions and thoughtful control strategies, novel enzymes can often be transformed into reliable screening systems faster than many teams expect.

Ultimately, the question is not just can assays be developed for novel enzyme targets, but whether they can be developed in a way that reduces risk, shortens timelines, and improves decision-making. When assay design is approached as a strategic enabler rather than a technical afterthought, novel targets are far more likely to progress from early curiosity to meaningful drug discovery programs.

Learn more about how BellBrook Labs Assay Development Services can accelerate your discovery and get you screening faster.

FAQs: Can BellBrook Labs Develop Assays for Novel Enzyme Targets?

1) Can BellBrook Labs develop assays for novel enzyme targets?

Yes—BellBrook Labs can develop assays for novel enzyme targets, especially when the target’s activity can be measured using universal biochemical readouts (like nucleotide or nucleotide-linked products) and translated into a robust, HTS-compatible format.

2) What types of novel enzyme targets are the best fit?

Novel targets that produce or consume nucleotides (ATP/ADP, GTP/GDP, AMP, cyclic nucleotides) or generate measurable biochemical products (like SAH or cGAMP) are often strong fits, because they can leverage scalable, homogeneous detection strategies.

3) Does BellBrook only develop assays for enzymes already in their catalog?

No. Assay development can support new enzyme targets, including emerging targets, as long as the target activity can be measured and the program can supply or source active enzyme and substrates. Novelty isn’t the barrier—measurability and robustness are.

4) How long does it typically take to develop an HTS-ready assay for a novel enzyme target?

Timelines vary based on enzyme availability and assay complexity. Targets with clear chemistry and stable enzyme often progress faster; difficult proteins or uncertain reaction requirements can take longer due to upstream biochemistry constraints.

5) What does “HTS-ready” mean in practice?

HTS-ready generally means the assay is reproducible in 384- or 1536-well plates, tolerant to DMSO, statistically robust (strong Z’ factor), and operationally simple enough for automation—while maintaining a low false-positive rate.

6) Can BellBrook develop assays that work for both hit finding and SAR?

That’s typically the goal. A strong assay development project designs the primary assay to support library screening, then builds a plan for confirmation and triage so medicinal chemistry teams can trust early SAR.

7) What if the enzyme doesn’t produce a convenient detectable product?

If the enzyme doesn’t yield a directly measurable product, the project may require coupling strategies, alternative substrates, or orthogonal/confirmatory methods. In some cases, LC-MS or radiometric confirmation is used to validate the screening assay.

8) How do you reduce false positives when screening novel enzyme targets?

False positives are reduced through assay design (appropriate controls, detergents when needed, interference-aware detection) and through triage strategy: orthogonal confirmation assays, counter-screens, and analytical follow-up on suspicious chemotypes.

9) Can assays be designed to compare selectivity across related enzymes?

Often yes—especially if the readout is universal. Selectivity profiling works best when assays share similar conditions and detection strategies so differences reflect biology rather than assay format.

10) What should a team provide to start an assay development project for a novel enzyme target?

Typically: target background and reaction knowledge, available enzyme construct(s) or expression plan, substrates/cofactors, desired assay format (screening vs profiling), throughput goals, and any known tool compounds or reference inhibitors if they exist.